United States Small Molecule CDMO Market to Grow with a CAGR of 5.70% through 2030
Surge in
research and development activities is expected to drive the United States Small
Molecule CDMO Market growth in the forecast period, 2026-2030.
According to
TechSci Research report, “United States Small Molecule CDMO Market – By
Region, Competition, Forecast & Opportunities, 2030F”, the United
States Small Molecule CDMO Market stood at USD 25.37 Billion in 2024 and is
anticipated to grow with a CAGR of 5.70% through 2030. Initiatives taken by
government based on small molecule CDMO has led to favorable market conditions
for the United States Small Molecule CDMO Market. Several factors contribute to
the growth of various small molecule CDMO products.
The U.S.
government has implemented several initiatives to bolster the domestic small
molecule CDMO (Contract Development and Manufacturing Organization) market,
aiming to enhance pharmaceutical manufacturing capabilities and reduce reliance
on foreign production. These efforts are particularly pertinent in the context
of increasing demand for small molecule drugs, driven by factors such as the
growing prevalence of chronic diseases and advancements in oncology treatments. One significant initiative is the FDA Prechecks
program. This program seeks to streamline regulatory processes for domestic
drug manufacturing facilities by facilitating early engagement with the FDA
during facility planning and design.
The surge in research and development (R&D) activities is a key driver fueling the growth of the United States small molecule CDMO market. As pharmaceutical and biotechnology companies intensify efforts to discover and develop new therapies, the demand for specialized development and manufacturing services has increased significantly. This heightened R&D focus is particularly evident in areas such as oncology, infectious diseases, and rare disorders, where innovative small molecule drugs are being rapidly advanced through clinical pipelines.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "United States Small Molecule CDMO Market”
The United
States Small Molecule CDMO Market is segmented into product, application, regional
distribution, and company.
Based
on Product, Finished Drug Products have emerged as the dominating segment in
the United States Small Molecule CDMO Market in 2024. This is due to its
critical role in the pharmaceutical supply chain and increasing demand for
end-to-end outsourcing solutions. Pharmaceutical companies are increasingly
relying on CDMOs to handle formulation development, clinical and commercial
manufacturing, packaging, and labeling to streamline operations and reduce
time-to-market. This comprehensive service offering allows drug developers to
focus on core competencies such as research and marketing, while leveraging the
specialized expertise and advanced manufacturing capabilities of CDMOs for
finished product development.
Based on Region,
Northeast have emerged as the fastest growing region in the United States Small
Molecule CDMO Market in 2024. This is due to its strong concentration of
pharmaceutical and biotechnology companies, world-class research institutions,
and advanced infrastructure. This region benefits from a robust ecosystem that
fosters innovation and collaboration, attracting significant investment in drug
development and manufacturing.
Major companies
operating in United States Small Molecule CDMO Market are:
- Lonza
- Catalent, Inc.
- Thermo Fisher
Scientific Inc.
- Cambrex
Corporation
- Bellen Chemistry
- Siegfried
Holding AG
- Recipharm AB
- Eurofins
Scientific
- Aurigene
Pharmaceutical Services Ltd
- CordenPharma
International
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“Nanotechnology
is becoming an increasingly important aspect of the United States Small
Molecule CDMO market, offering significant opportunities for innovation and
enhanced drug development. By enabling the manipulation of materials at the
molecular and atomic levels, nanotechnology allows CDMOs to develop more
precise and effective small molecule formulations. This leads to improved drug
solubility, targeted delivery, and controlled release, which ultimately enhance
therapeutic outcomes and patient compliance”, said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“United States
Small Molecule CDMO Market By Product (Active Pharmaceutical Ingredients (API),
Finished Drug Products, Others), By Application (Oncology, Cardiovascular
Disease, Central Nervous System (CNS) Conditions, Autoimmune/Inflammation,
Others), By Region, Competition, Forecast & Opportunities, 2020-2030F”,
has evaluated the future growth potential of United States Small Molecule CDMO
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in United States Small
Molecule CDMO Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com